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Paget disease of bone (PDB) is characterized by increased osteoclast activity and localized abnormal bone remodeling.
PDB has a significant genetic component, with evidence of linkage to chromosomes 6p21.3 (PDB1) and 18q21-
22 (PDB2) in some pedigrees. There is evidence of genetic heterogeneity, with other pedigrees showing negative
linkage to these regions. TNFRSF11A, a gene that is essential for osteoclast formation and that encodes receptor
activator of nuclear factor-k B (RANK), has been mapped to the PDB2 region. TNFRSF11Amutations that segregate
in pedigrees with either familial expansile osteolysis or familial PDB have been identified; however, linkage studies
and mutation screening have excluded the involvement of RANK in the majority of patients with PDB. We have
excluded linkage, both to PDB1 and to PDB2, in a large multigenerational pedigree with multiple family members
affected by PDB. We have conducted a genomewide scan of this pedigree, followed by fine mapping and multipoint
analysis in regions of interest. The peak two-point LOD scores from the genomewide scan were 2.75, at D7S507,
and 1.76, at D18S70. Multipoint and haplotype analysis of markers flanking D7S507 did not support linkage to
this region. Haplotype analysis of markers flanking D18S70 demonstrated a haplotype segregating with PDB in a
large subpedigree. This subpedigree had a significantly lower age at diagnosis than the rest of the pedigree
( vs. years; ). Linkage analysis of this subpedigree demonstrated a peak two-point51.2 8.5 64.2 9.7 Pp .0012
LOD score of 4.23, at marker D18S1390 ( ), and a peak multipoint LOD score of 4.71, at marker D18S70.vp 0
Our data are consistent with genetic heterogeneity within the pedigree and indicate that 18q23 harbors a novel
susceptibility gene for PDB.
Paget disease of bone (PDB [MIM 167250; MIM
602080), or osteitis deformans, is a skeletal disorder of
unknown cause. This disease is characterized by exces-
sive and abnormal bone remodeling due to increased
bone resorption followed by disorganized bone forma-
tion (Krane 1986). PDB is the second-most-common
metabolic bone disease (after osteoporosis), affecting
∼3% of the population at age 140 years (Siris 1998). It
is more common in Western countries; conversely, it is
extremely rare in China and most of sub-Saharan Africa
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(Rosenbaum and Hanson 1969; Detheridge et al. 1982).
Reports of familial clustering, coupled with the demo-
graphics of PDB, indicate that genetic factors play an
important role in its etiology. In 1972, an autosomal
dominant mode of inheritance was proposed (McKusick
1972). Familial-aggregation studies indicate that sub-
jects with a first-degree relative affected by PDB have a
relative risk of 7 for developing the disease (Siris et al.
1991). A recent study from Spain, utilizing bone scans
to identify subclinical disease, documented that 40% of
patients had at least one affected first-degree relative
(Morales-Piga et al. 1995).
Because of the late age at onset and the difficulty of
ascertaining informative multiplex pedigrees, there has
been a relative paucity of family studies of PDB. The
PDB1 (MIM 167250) locus (HLA region, 6p21.3) was
identified by Fotino et al. (1977) and was later supported
by Tilyard et al. (1982); however, other linkage studies
have failed to confirm these results (Breanndan Moore
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Figure 1 Pedigree structure. The shaded symbols indicate subjects affected by PDB, and the arrow indicates the proband.
and Hoffman 1988). A recent report suggests that the
HLA locus is unlikely to play a major role in the etiology
of PDB (Laurin et al. 1999).
Familial expansile osteolysis (FEO [MIM 174810]) is
a rare, autosomal dominant bone disorder sharing some
characteristics with PDB. FEO has been described in a
large Northern Irish pedigree (Osterberg et al. 1988;Wal-
lace et al. 1989). The gene responsible for FEO has been
linked to a region of chromosome 18q21.2-18q21.3
(Hughes et al. 1994). Positive linkage to this region has
also been reported in some families with PDB (Cody et
al. 1997; Haslam et al. 1998). This region is referred to
as the “PDB2 locus” (MIM 602080). Cody et al. (1997)
documented a maximum two-point LOD score of 3.40,
at marker D18S42, in a large pedigree with PDB. One
subject had PDB but did not carry the putative disease
haplotype. The PDB region was bounded proximally by
a recombination event at D18S39; however, the distal
boundary was undefined, and it is possible that the region
of linkage in this pedigree extends telomerically.
Approximately 1% of patients with PDB develop os-
teosarcoma (Hadjipavlou et al. 1992). Analysis of tu-
mor-specific loss of constitutional heterozygosity in spo-
radic and Pagetic osteosarcomas has identified a putative
tumor-suppressor locus within the PDB2 region (Nel-
lissery et al. 1998).
TNFRSF11A (MIM 603499), a gene essential for os-
teoclast formation that encodes receptor activator of nu-
clear factor-k B (RANK), has been mapped to the PDB2
region (Hughes et al. 2000). Recent studies have iden-
tified in exon 1 of TNFRSF11A an 18-bp insertion seg-
regating with patients with FEO and a 27-bp insertion
in exon 1 in families with PDB (Hughes et al. 2000).
Affected individuals in a family with PDB studied by
Hughes et al. (2000) did not express classical PDB, since
subjects presented with bone pain or deformity in their
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Table 1
Summary of Clinical Features of Living, Affected Individuals from the Pedigree
PATIENTa
AGE AT
DIAGNOSIS
(years)
CURRENT TREATMENT
SAP
(U/liter) DISTRIBUTION OF DISEASEStatus Duration
III-11 76 Newly diagnosed … 125 Pelvis, right scapula
IV-10 59 Nil to date 24 years 2,230 Femur
IV-26 58 Newly diagnosed … 673 Extensive polyostotic disease
IV-28 55 Pamidronate 2 years 353 Extensive polyostotic disease
IV-33 58 Alendronate 1 year 180 Humerus
IV-37 58 Alendronate 2 mo 673 Both femora
IV-45 74 Newly diagnosed … 77 Skull
IV-46 62 Alendronate 6 mo 1,697 Skull, vertebrae, pelvis, right femur, humerus
IV-48 60 Pamidronate 26 years 977 Extensive polyostotic disease
IV-57 84 Newly diagnosed … 63 Left hip, left maxilla
V-05 53 Newly diagnosed … 114 L3 vertebra, right humeral head, left tibia
V-18 58 Newly diagnosed … 273 Cervical spine, L1 vertebra, sacrum, right pelvis, left femur
V-19 61 Newly diagnosed … 147 Scapula, sacrum, pelvis, tibia, right calcaneum
V-21 55 Alendronate 2 years 50 Skull, right femur, pelvis
V-37 59 Newly diagnosed … 159 Skull, left femur, left tibia, right ischium, left acetabulum
V-39 36 Pamidronate 6 years 400 Pelvis, left femur, right humerus
V-41 58 Alendronate 2 years 61 Skull, shoulder, pelvis, hips
V-43 62 Newly diagnosed … 239 Skull, left humerus, right tibia, left femur, right hemipelvis, vertebrae
V-48 49 Newly diagnosed … 166 Left himipelvis and sacrum
V-53 46 Newly diagnosed … 100 Left scapula
V-56 31 Newly diagnosed … 86 Distal left tibia
V-59 55 Newly diagnosed … 98 Right calcaneum
V-64 48 Newly diagnosed … 105 Skull, femora
V-73 50 Alendronate 1 year 366 Vertebrae, pelvis, left femur
V-74 60 Alendronate 2 years 92 Rib, shoulder, femora, tibiae
V-75 52 Alendronate 2 years 93 Femora, pelvis, base of skull
V-80 50 Alendronate 3 mo 363 Pelvis, base of skull
V-102 69 Nil to date … 246 Left tibia, left shoulder, left femur
V-104 70 Newly diagnosed … 126 Right femur
V-108 53 Newly diagnosed … 106 Right tibia, skull
a Patient identity numbers are read counterclockwise from the pedigree diagram (fig.1).
teens and early 20s. Unlike the families with FEO, af-
fected individuals have involvement of the axial skele-
ton, with lesions in the spine, pelvis, and mandible, as
well as at sites associated with lesions in FEO. All af-
fected patients have dental problems, and several have
hearing impairment. These insertions affect the signal-
peptide region of the RANK molecule and cause an in-
crease in RANK-mediated nuclear factor-k B signaling
in vitro, consistent with the presence of an activating
mutation (Hughes et al. 2000). Expression of recom-
binant forms of the mutant RANK proteins revealed
perturbations in expression levels and the lack of normal
cleavage of the signal peptide. A recent Australian study
excluded TNFRSF11A exon 1 mutations in 82 patients
with sporadic PDB and in 23 patients with familial PDB
(Kormas et al. 2000).
Haslam et al. (1998) undertook linkage analysis in a
number of multiplex pedigrees with PDB that were from
diverse ethnic backgrounds, and they demonstrated ex-
clusion of linkage with the PDB2 locus in some pedi-
grees, thus providing evidence of genetic heterogeneity.
Recently, Laurin et al. (2001) performed genetic linkage
analysis in 24 large French-Canadian families with PDB.
The strongest evidence of linkage was on chromosome
5q35-qter, with a maximum LOD score of 8.58 under
heterogeneity. In the 24 families, all patients from 8 fam-
ilies contained the same characteristic haplotype. The
other 16 families were analyzed, resulting in themapping
of a second locus, at 5q31, with a maximum LOD score
of 3.70.
We have identified a large pedigree in which PDB ap-
pears to be inherited as an autosomal dominant trait
(fig. 1). We have previously documented significantly
negative LOD scores at the PDB1 and PDB2 loci in this
pedigree (Good et al. 2001). We have proceeded with
full-genome linkage analysis and have identified a novel
susceptibility locus at 18q23, ∼20 Mb telomeric of
TNFRSF11A (UCSC Human Genome Project Working
Draft [“Golden Path”]).
Clinical characteristics of the pedigree are summarized
in table 1 and are described elsewhere (Good et al. 2001).
Previous diagnosis of PDB was confirmed by review of
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Figure 2 Summary of two-point LOD scores, by chromosome, generated by genomewide scan
Figure 3 Multipoint LOD scores for chromosome 7 markers flanking D7S507, analyzed for entire pedigree. Positions given are sex-
averaged distances and are from the Genetics Location Database.
medical notes and bone scans. Study participants un-
derwent measurement of the serum total alkaline phos-
phatase (SAP), with reference range 40–110 U/liter. Sub-
jects with symptoms suggestive of PDB and/or with SAP
160 U/liter underwent bone scan and skeletal radio-
graphs. The diagnosis of PDB was made on the basis of
either the bone scan or radiological evidence. Asymp-
tomatic subjects aged 160 years and with SAP levels60
U/liter were considered to be unaffected. Unaffected sub-
jects aged !60 years were considered to be of unknown
status, to allow for age-dependent penetrance (Ooi and
Fraser 1997). It is possible that these diagnostic criteria
may have misclassified some affected patients with in-
active or localized disease.
DNA was extracted from blood samples by the salt-
ing-out method (Miller et al. 1988). Subjects were ini-
tially genotyped using a genetic map consisting of 400
autosomal markers with anticipated mean  SD het-
erozygosity of , at the Australian Genome0.74 0.11
Research Facility (AGRF) (Ewen et al. 2000). The mean
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Figure 4 Haplotype analysis of representative sample of subpedigree, for chromosome 18q23. This subpedigree, which shows significant
linkage to 18q23, is descended from subject III-3. The haplotype that segregates with PDB in the subpedigree is indicated by the black bar;
haplotypes in parentheses are inferred. Subject III-3 had 13 offspring, but, in the interests of space and clarity, only 5 are shown here; subject
IV-34 had 11 offspring, but, in the interests of space and clarity, only 4 are shown here. The putative affected haplotype, with the exception
of three apparent phenocopies, is shared by all affected descendants of subject III-3.
 SD sex-averaged distance between adjacent markers
is cM (range 0–34 cM). The genomewide scan8.6 6.5
was performed on 61 individuals from the pedigree, 27
of whom were affected with PDB.
Genetic linkage analysis was performed using FAST-
LINK v4.1 (Cottingham et al. 1993; Scha¨ffer et al.
1994). Relationships between sibs were verified using
RELATIVE (Go¨ring and Ott 1997). On the basis of the
pedigree data, we assumed an autosomal dominant
mode of inheritance with disease penetrance set at 90%.
We assumed a trait-allele frequency of 0.01 and a phe-
nocopy rate of 2.3%, which yield a population preva-
lence of 4% and a sibling recurrence risk of 0.225
( ). These are consistent with Australian epide-l p 5.6s
miological data for PDB (Gardner et al. 1978). Simple
counting estimates have been used to calculate allelic
frequencies in the pedigree, to avoid errors. Differences
in age at diagnosis were analyzed using the Wilcoxon
rank-sum test (Wilcoxon 1945).
Peak two-point LOD scores from the genomewide scan
are presented in figure 2. Under the criteria of Rao and
Province (2000), a P value !.0023, which corresponds to
a LOD score 1.75, is considered to be highly suggestive
evidence of linkage (Rao and Province 2000). Suggestive
linkage was indicated on chromosomes 7p21 and 18q23,
with peak two-point LOD scores of 2.75 ( ), atvp 0.1
D7S507, and 1.76 ( ), at D18S70. To ensure thatvp 0.1
all markers were genotyped for the same number of in-
dividuals, missing genotypes were completed, and further
fine mapping was performed, by manual genotyping in
our laboratory, as described elsewhere (Good et al. 2001).
Fine mapping in the chromosomes 7 and 18 regions was
undertaken for 88 pedigree members, 30 of whom are
affected by PDB. Genotyping for genomewide-scanmark-
ers in the region of interest was repeated manually, to
confirm the genomewide-scan results for this marker.
The multipoint LOD scores generated by fine mapping
in the region of positive linkage on chromosome 7 are
shown in figure 3, with peak multipoint LOD score of
0.62 at marker D7S508. These results failed to support
evidence of linkage in the region flankingmarkerD7S507.
Haplotype analysis of genotyped individuals by use of
markers spanning 15 cM flanking D7S507 showed no
evidence of a disease haplotype segregating in the pedi-
gree. We concluded that, taken in conjunction with the
multipoint analysis, this region was not linked to PDB in
this pedigree.
Haplotype analysis of markers flanking the region of
interest on chromosome 18q23 was conducted using six
markers spanning a 9-cM region telomeric to and in-
cluding D18S1161 (the Genetics Location Database). For
deceased individuals, haplotypes were inferred. A distinct
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Table 2
Two-Point LOD Scores for Chromosomal Region 18q, for the Subpedigree
MARKER
POSITIONa
(cM)
LOD SCORE AT v p
.00 .01 .05 .10 .20 .30 .40
D18S474 71.3 6.62 5.75 4.05 2.91 1.44 .59 .14
PDB2 region:
D18S64 86.37 1.27 1.09 .70 .46 .19 .04 .00
D18S60 94.83 4.83 3.83 2.34 1.46 .59 .19 .04
D18S68 98.73 3.78 3.08 1.99 1.25 .46 .13 .02
D18S42 98.99 2.82 2.52 1.87 1.48 1.01 .62 .29
D18S483 100.82 2.64 2.28 1.41 .84 .33 .15 .08
D18S878 100.93 1.07 .91 .5 .22 .04 .11 .04
D18S466 104.83 2.67 2.30 1.52 .95 .31 .06 .00
D18S61 105.43 1.17 1.03 .85 .76 .42 .15 .03
D18S1161 114.17 3.24 2.98 2.02 1.22 .41 .09 .01
D18S50 117.91 1.74 1.73 1.67 1.55 1.22 .77 .25
D18S462 119.29 2.70 2.73 2.74 2.60 2.07 1.31 .45
D18S1122 119.55 1.20 1.21 1.21 1.15 .90 .54 .14
D18S70 119.84 4.01 3.99 3.83 3.50 2.63 1.62 .59
D18S1390 119.84 4.23 4.16 3.85 3.42 2.46 1.43 .46
NOTE.— The subpedigree is composed of descendants of subject III-3 (fig. 1). The subpedigree is a large
family, in which the age at onset of PDB is earlier than that in the rest of the pedigree.
a Sex-averaged distances from the Genetics Location Database.
haplotype was noted to segregate with PDB in a large
subpedigree (descendants of subject III-3; fig. 4). This larg-
est branch of the family consists of 54 genotyped study
participants, including 17 living subjects affected with
PDB; in addition, the genotypes of 4 deceased affected
subjects can be inferred. This subpedigree has an earlier
age at onset of PDB than the remainder of the pedigree;
mean SD age at diagnosis was years versus51.2 8.5
years ( ). This subpedigree demon-64.2 9.7 Pp .0012
strated a peak two-point LOD score of 4.23 at , atvp 0
marker D18S1390 (table 2). Multipoint linkage analysis
of the subpedigree yielded a peak LOD score of 4.71, at
marker D18S70 (fig. 5). The multipoint LOD score was
significantly negative at the PDB2 locus in this subpedi-
gree (fig. 5). At D7S507, the maximum LOD score for
this subpedigree was 1.35 at . The linked hap-vp 0
lotype at 18q23 (illustrated in fig. 4) is present in 18 of
the 21 affected subjects in the subpedigree. Nine subjects
aged !60 years (mean age ) have the at-risk50.4 7.4
haplotype but currently show no radiological evidence of
PDB. The mean  SD SAP level of these subjects was
U/liter. There are three apparent phenocopies88 14.2
in the subpedigree. One of these subjects (IV-22) is de-
ceased and was diagnosed as having PDB in the cervical
spine, at the age of 83 years, on the basis of plain radi-
ographs. These radiographs were not available for our
review. Her four offspring, aged 63–71 years, are, at pre-
sent, unaffected by PDB. The other two apparent phe-
nocopies were diagnosed at the ages of 58 (V-41) and 62
(V-43) years. Their mother and two affected siblings carry
the at-risk haplotype. Their father was deceased at the
time of the clinical study. He had had symptoms sugges-
tive of PDB but had not undergone biochemical or ra-
diological evaluation and, for the linkage analysis, was
considered to be of unknown status.
Total genomic DNA of subjects from the pedigree
was sequenced to assess for mutations in exon 1 of
TNFRSF11A. Mutations in exon 1 were analyzed by
sequencing of PCR products by use of Big Dye Ter-
minator (Applied Biosystems). PCR conditions were
as described by Hughes et al. (2000) and incorporat-
ed the following primer pair: forward, 5′-TGGGTACC-
ACCTGGCTGGCAC-3′; and reverse, 5′-AAGGCGG-
AGGAGCCAGGATGC-3′. Gel separation was per-
formed by the AGRF, on an ABI 377. Affected subjects
from the pedigree, including four from the subpedi-
gree with an earlier age at onset (descendants of sub-
ject III-3; fig. 4), were examined. Unaffected subjects
from this subpedigree were also examined. No mu-
tations were identified in the coding sequence in ei-
ther affected or unaffected subjects. In three of the
affected subjects, two previously reported nonfunc-
tional polymorphisms were noted: 1 G/A close to
the start position of transcription and 30 T/C within
the 5′ UTR, nine bases before the initiation codon
(Hughes et al. 2000).
Analysis of the kindred, excluding the subpedigree in
which PDB maps to 18q23, failed to identify additional
significant regions of linkage. The following secondary
peak LOD scores were obtained from this analysis: 1.34,
at D21S266, and 1.66, at D9S1776.
Our data raise the possibility of genetic heterogeneity
within the pedigree, as has elsewhere been demonstrated
for pedigrees with type 2 diabetes and maturity-onset di-
Reports 523
Figure 5 Multipoint LOD scores for chromosome 18 markers, in subpedigree. Positions given are sex-averaged distances and are from
the Genetics Location Database. The PDB2 region is indicated.
abetes of the young (Stoffel et al. 1992; Yamagata et al.
1996). It is possible that the susceptibility-gene mutation
that was localized to 18q23maymodulate the age at onset
of the PDB phenotype in this pedigree. Chromosome
18q23 has not previously been implicated in the etiology
of PDB. The negative linkage data at 18q21.3 and the
absence of mutations in exon 1 of TNFRSF11A support
exclusion of this gene as causative in this pedigree.
A number of candidate genes are located in the vicinity
of the maximum LOD score. One of these candidates,
NFATc1, is a member of the NFAT (nuclear factor of
activated T cells) family of genes. The NFAT family of
transcription factors play a pivotal role in the transcrip-
tion of many genes critical for the immune response,
including the genes for cytokines IL2, IL4 granulocyte-
macrophage colony-stimulating factor (GM-CSF), and
tumor-necrosis factor-a (Rao et al. 1997). Furthermore,
1,25 (OH)2D3 repression of IL2 and GM-CSF transcrip-
tion has been shown to be affected by competition be-
tween the vitamin D receptor and NFATc2 (Alroy et al.
1995; Towers et al. 1999), suggesting a possible pathway
by which NFATc1 mutations could be implicated in
PDB. NFAT transcription factors have also been shown
to regulate osteoclast-specific expression of the calcito-
nin receptor and tartrate-resistant acid phosphatase
genes (Galson et al. 2000).
PDB is a complex, genetically heterogeneous disorder
that may result from the joint action of and interaction
between genetic and environmental factors. We have as-
certained a large pedigree with familial PDB. We have
excluded linkage with the PDB1 and PDB2 regions,
have excluded mutations in exon 1 of TNFRSF11A, and
have identified a novel susceptibility locus for PDB, at
chromosome 18q23, in a large subpedigree. Several can-
didate genes have been identified in the region, and we
plan to continue to use fine mapping, haplotype analysis,
and sequence analysis to identify the nature of the sus-
ceptibility gene. The identification of genetic markers for
PDB is fundamental for understanding the cause of the
disease; for identifying, at a preclinical stage, subjects at
risk; and for the development of more-effective preven-
tive and therapeutic strategies for the management of
the condition.
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